A Prospective, Multi-center Clinical Trial for Evaluating the Effectiveness and Safety of Online Coronary Angiography-Derived Index of Microcirculatory Resistance in STEMI Patients (Flash IV)

Status: Recruiting
Location: See all (8) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

Despite the success of restoration of epicardial blood flow by the primary percutaneous coronary intervention (PPCI), approximately a half of patients with ST-segment elevation myocardial infarction (STEMI) have failed myocardial reperfusion, as reflected by microvascular obstruction (MVO) and intramyocardial haemorrhage (IMH). The coronary angiography-derived index of microvascular resistance (caIMR) is a brand new method for assessing coronary microcirculation in ischemia and no obstructive coronary artery disease (INOCA). In this trial, the investigators aim to verify the safety and effectiveness of caIMR in STEMI who underwent primary PCI. The investigators will immediately measure the caIMR of patients who successfully underwent pPCI, and combine the caIMR with the long-term prognosis, to verify the prognostic performance of caIMR.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Aged between 18 and 80, regardless of gender;

• Initially diagnosed as STEMI and underwent primary PCI;

• Voluntarily participated in this trial and signed the informed consent form.

Locations
Other Locations
China
Beijing Luhe Hospital.Capital Medical University
NOT_YET_RECRUITING
Beijing
Peking University First Hospital
NOT_YET_RECRUITING
Beijing
Huai'an First People's Hospital
NOT_YET_RECRUITING
Huai'an
The First People'S Hospital of Lianyungang
NOT_YET_RECRUITING
Lianyungang
General Hospital of Xuzhou Mining Group
NOT_YET_RECRUITING
Xuzhou
The Affiliated Hospital of Xuzhou Medical University
RECRUITING
Xuzhou
Xuzhou Central Hospital
NOT_YET_RECRUITING
Xuzhou
Xuzhou First People's Hospital
NOT_YET_RECRUITING
Xuzhou
Contact Information
Primary
Lu Yuan
luyuan329@163.com
86-13952110901
Time Frame
Start Date: 2023-11-01
Estimated Completion Date: 2025-05-31
Participants
Target number of participants: 335
Treatments
high caIMR
caIMR≥25
low caIMR
caIMR\<25
Sponsors
Collaborators: RainMed Medical Group
Leads: The Affiliated Hospital of Xuzhou Medical University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials